BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL
You may also be interested in...
Earnings Bleak, BioMarin Scrambles To In-License
Kuvan-launch mistakes and the Riquent fizzle take their toll, as company shops for workable assets.
Earnings Bleak, BioMarin Scrambles To In-License
Kuvan-launch mistakes and the Riquent fizzle take their toll, as company shops for workable assets.
BioMarin Deal For La Jolla’s Riquent Rights Comes In Nick Of Time
BioMarin could get 50 percent of revenues for very little upfront.